Corganics, a clinical cannabinoid (CBD) company, announced a patient access partnership with OrthoLoneStar, an independent orthopedic practice in Texas. The partnership provides OrthoLoneStar patients access to Corganics’ clinical CBD therapies throughout OrthoLoneStar’s locations.

OrthoLoneStar is an integrated private practice group comprised of more than 1150 employees and 169 physicians treating patients at 46 sites across Texas. OrthoLoneStar physicians treat the full range of orthopedic issues in its Advanced Orthopaedics and Sports Medicine, Carrell Clinic, Azalea Orthopedics, Texas Orthopedic Associates and Fondren Orthopedic Group locations.

“OrthoLoneStar cares deeply about the quality and safety of therapy options for our patients,” stated Anthony Brooks, CEO of OrthoLoneStar. “We have partnered with Corganics to provide access to cannabinoid therapy that is high quality and independently tested to ensure potency, transparency and consistency.”

Corganics’ products are third-party tested in ISO-certified labs and manufactured in a cGMP compliant and NSF certified facility. Corganics’ clinical CBD therapy products also contain no detectable THC and can only be purchased directly through healthcare professionals or with a referral from their healthcare professional.

“Patients are treating themselves with retail CBD products that may or may not have the advertised content,” stated Robert Scheinberg, M.D., orthopedic surgeon and member of the OrthoLoneStar board of…